BioWorld Asia

Jan. 30, 2002

UroGene, Pierre Fabre Enter 3-Year Cancer Collaboration

PARIS UroGene SA entered into a three-year research collaboration with Pierre Fabre M dicament to discover and develop new active compounds to treat prostate cancer against a validated biological target identified by UroGene. (BioWorld International) Read More

Symphogen Raises US$15M To Develop Polyclonal Antibodies

Peptide Study Yields Insights Into Autoimmune Disease Mechanisms

Synt:em, Baxter Collaborate On Peptide Mimetics Of MAbs

UK Creating Centers To Help Capitalize On Genetics Progress

Galapagos, Exelixis Collaborate To Analyze Functions Of Genes

Biogen Paying Schering $20M Or More Over MS Drug Patents

BIA Calls For More Support To Deal With Animal Rights Activists

Dutch Biotech Association Seeks Clearer Signals From Politicians

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 19, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 19, 2025.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...